Chemotherapy and chemoprevention by thiazolidinediones

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Fröhlich, Eleonore ^a   Wahl, Richard ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLON CANCER; COLORECTAL CANCER; CONFORMATIONAL TRANSITION; DIABETES MELLITUS; DIFFERENTIATED THYROID CANCER; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; GLIOBLASTOMA; GLIOMA; HUMAN; LIPOSARCOMA; LUNG CANCER; MELANOMA; MONOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SOFT TISSUE SARCOMA; THYROID CANCER; TRANSCRIPTION INITIATION; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; PATHOLOGY; THYROID NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; PPAR GAMMA; THIAZOLIDINEDIONES; THYROID NEOPLASMS;

EID: 84926432198     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/845340     Document Type: Review

References (146)

1. S. Malik, P. K. Upadhyaya, and S. Miglani, "Thiazolidinediones: a plethro of biological load," International Journal of PharmTech Research, Vol. 3, no. 1, pp. 62-75, 2011.
2. J. Youssed and M. Badr, "PPAR ligands," in Peroxisome Proliferator-Activated Receptors: Discovery and Recent Advances, J. Youssed and M. Badr, Eds., Springer Science+Business Media, New York, NY, USA, 2013.
3. R. L. Koffarnus, K. A. Wargo, and H. M. Phillippe, "Rivoglitazone: a new thiazolidinedione for the treatment of type 2 diabetes mellitus," Annals of Pharmacotherapy, Vol. 47, no. 6, pp. 877-885, 2013.
4. T. Imchen, J. Manasse, K.-W. Min, and S. J. Baek, "Characterization of PPAR dual ligand MCC-555 in AOM-induced colorectal tumorigenesis," Experimental and Toxicologic Pathology, Vol. 65, no. 6, pp. 919-924, 2013.
5. E. Mylona, I. Giannopoulou, K. Diamantopoulou et al., "Peroxisome proliferator-activated receptor gamma expression in urothelial carcinomas of the bladder: association with differentiation, proliferation and clinical outcome," European Journal of Surgical Oncology, Vol. 35, no. 2, pp. 197-201, 2009.
6. S. Nomura, A. Nakajima, S. Ishimine, N. Matsuhashi, T. Kadowaki, and M. Kaminishi, "Differential expression of peroxisome proliferator-activated receptor in histologically different human gastric cancer tissues," Journal of Experimental and Clinical Cancer Research, Vol. 25, no. 3, pp. 443-448, 2006.
7. I. Papadaki, E. Mylona, I. Giannopoulou, S. Markaki, A. Keramopoulos, and L. Nakopoulou, "PPARγ expression in breast cancer: clinical value and correlation with ERβ," Histopathology, Vol. 46, no. 1, pp. 37-42, 2005.
8. G. Y. Zhang, N. Ahmed, C. Riley et al., "Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma," British Journal of Cancer, Vol. 92, no. 1, pp. 113-119, 2005.
9. L. Yao, F. Liu, L. Sun et al., "Upregulation of PPARγ in tissue with gastric carcinoma," Hybridoma, Vol. 29, no. 4, pp. 341-343, 2010.
10. M. Pancione, L. Sabatino, A. Fucci et al., "Epigenetic silencing of peroxisome proliferator-activated receptor γ is a biomarker for colorectal cancer progression and adverse patients' outcome," PLoS ONE, Vol. 5, no. 12, Article ID e14229, 2010.
11. S. Ogino, K. Shima, Y. Baba et al., "Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis," Gastroenterology, Vol. 136, no. 4, pp. 1242-1250, 2009.
12. M. Nickkho-Amiry, R. McVey, and C. Holland, "Peroxisome proliferator-activated receptors modulate proliferation and angiogenesis in human endometrial carcinoma," Molecular Cancer Research, Vol. 10, no. 3, pp. 441-453, 2012.
13. C. K. Glass and K. Saijo, "Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells," Nature Reviews Immunology, Vol. 10, no. 5, pp. 365-376, 2010.
14. M. J. Pishvaian, J. L. Marshall, A. J. Wagner et al., "A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies," Cancer, Vol. 118, no. 21, pp. 5403-5413, 2012.
15. X. Sun, J. D. Ritzenthaler, Y. Zheng, J. Roman, and S. Han, "Rosiglitazone inhibits α4 nicotinic acetylcholine receptor expression in human lung carcinoma cells through peroxisome proliferator-activated receptor γ-independent signals," Molecular Cancer Therapeutics, Vol. 8, no. 1, pp. 110-118, 2009.
16. F. Chen and L. E. Harrison, "Ciglitazone-induced cellular antiproliferation increases p27 kip1 protein levels through both increased transcriptional activity and inhibition of proteasome degradation," Cellular Signalling, Vol. 17, no. 7, pp. 809-816, 2005.
17. D. Panigrahy, S. Singer, L. Q. Shen et al., "PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis," The Journal of Clinical Investigation, Vol. 110, no. 7, pp. 923-932, 2002.
18. B. Shen, E. S. H. Chu, G. Zhao et al., "PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice," British Journal of Cancer, Vol. 106, no. 9, pp. 1486-1494, 2012.
19. A. Galli, E. Ceni, D. W. Crabb et al., "Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARγ independent mechanisms," Gut, Vol. 53, no. 11, pp. 1688-1697, 2004.
20. P. E. Moss, B. E. Lyles, and L. V. Stewart, "The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells," Experimental Cell Research, Vol. 316, no. 20, pp. 3478-3488, 2010.
21. B. E. Lyles, T. O. Akinyeke, P. E. Moss, and L. V. Stewart, "Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARγ-dependent and PPARγ-independent pathways," Cell Cycle, Vol. 8, no. 2, pp. 268-277, 2009.
22. A. Mantovani and A. Sica, "Macrophages, innate immunity and cancer: balance, tolerance, and diversity," Current Opinion in Immunology, Vol. 22, no. 2, pp. 231-237, 2010.
23. R. Seger and E. G. Krebs, "The MAPK signaling cascade," FASEB Journal, Vol. 9, no. 9, pp. 726-735, 1995.
24. E. Burgermeister and R. Seger, "PPARγ and MEK interactions in cancer," PPAR Research, Vol. 2008, Article ID 309469, 16 pages, 2008.
25. X. Li, X. Yang, Y. Xu, X. Jiang, F. Nan, and H. Tang, "Troglitazone inhibits cell proliferation by attenuation of epidermal growth factor receptor signaling independent of peroxisome proliferator-activated receptor γ," Cell Research, Vol. 19, no. 6, pp. 720-732, 2009.
26. M. Dall'Asta, E. Derlindati, D. Ardigò, I. Zavaroni, F. Brighenti, and D. Del Rio, "Macrophage polarization: the answer to the diet/inflammation conundrum?" Nutrition, Metabolism and Cardiovascular Diseases, Vol. 22, no. 5, pp. 387-392, 2012.
27. F. Meisner, D. Walcher, F. Gizard et al., "Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial," Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 26, no. 4, pp. 845-850, 2006.
28. C. Ao, Y. Huo, L. Qi, Z. Xiong, L. Xue, and Y. Qi, "Pioglitazone suppresses the lipopolysaccharide-induced production of inflammatory factors in mouse macrophages by inactivating NF-κB," Cell Biology International, Vol. 34, no. 7, pp. 723-730, 2010.
29. E. Burgermeister, D. Chuderland, T. Hanoch, M. Meyer, M. Liscovitch, and R. Seger, "Interaction with MEK causes nuclear export and downregulation of peroxisome proliferatoractivated receptor γ," Molecular and Cellular Biology, Vol. 27, no. 3, pp. 803-817, 2007.
30. R. E. Nakles, B. V. S. Kallakury, and P. A. Furth, "The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency," The American Journal of Pathology, Vol. 182, no. 6, pp. 1976-1985, 2013.
31. N. Shimazaki, N. Togashi, M. Hanai et al., "Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model," European Journal of Cancer, Vol. 44, no. 12, pp. 1734-1743, 2008.
32. G. D. Demetri, C. D. Fletcher, E. Mueller et al., "Induction of solid tumor differentiation by the peroxisome proliferatoractivated receptor-γ ligand troglitazone in patients with liposarcoma," Proceedings of the National Academy of Sciences of the United States of America, Vol. 96, no. 7, pp. 3951-3956, 1999.
33. G. Debrock, V. Vanhentenrijk, R. Sciot, M. Debiec-Rychter, R. Oyen, and A. van Oosterom, "A phase II trial with rosiglitazone in liposarcoma patients," British Journal of Cancer, Vol. 89, no. 8, pp. 1409-1412, 2003.
34. Y. Dai and W. H. Wang, "Peroxisome proliferator-activated receptor gamma and colorectal cancer," World Journal of Gastrointestinal Oncology, Vol. 2, no. 3, pp. 159-164, 2010.
35. M. Pancione, N. Forte, L. Sabatino et al., "Reduced β-catenin and peroxisome proliferator-activated receptor-γ expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome," Human Pathology, Vol. 40, no. 5, pp. 714-725, 2009.
36. S. Theocharis, C. Giaginis, A. Parasi et al., "Expression of peroxisome proliferator-activated receptor-γ in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients' survival," Digestive Diseases and Sciences, Vol. 52, no. 9, pp. 2305-2311, 2007.
37. A. Gustafsson, E. Hansson, U. Kressner et al., "EP1-4 subtype, COX and PPARγ receptor expression in colorectal cancer in prediction of disease-specific mortality," International Journal of Cancer, Vol. 121, no. 2, pp. 232-240, 2007.
38. C. A. McAlpine, Y. Barak, I. Matise, and R. T. Cormier, "Intestinal-specific PPARγ deficiency enhances tumorigenesis in ApcMin/+ mice," International Journal of Cancer, Vol. 119, no. 10, pp. 2339-2346, 2006.
39. E. Osawa, A. Nakajima, K. Wada et al., "Peroxisome proliferator-activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice," Gastroenterology, Vol. 124, no. 2, pp. 361-367, 2003.
40. T. Yoshizumi, T. Ohta, I. Ninomiya et al., "Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects," International Journal of Oncology, Vol. 25, no. 3, pp. 631-639, 2004.
41. I. K. Choi, Y. H. Kim, J. S. Kim, and J. H. Seo, "PPAR-γ ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo," Investigational New Drugs, Vol. 26, no. 3, pp. 283-288, 2008.
42. T. Tsukahara and H. Haniu, "Peroxisome proliferator-activated receptor gamma overexpression suppresses proliferation of human colon cancer cells," Biochemical and Biophysical Research Communications, Vol. 424, no. 3, pp. 524-529, 2012.
43. M. H. Kulke, G. D. Demetri, N. E. Sharpless et al., "A phase II study of troglitazone, an activator of the PPARγ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer," Cancer Journal, Vol. 8, no. 5, pp. 395-399, 2002.
44. S. Theocharis, H. Kanelli, E. Politi et al., "Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade," Lung Cancer, Vol. 36, no. 3, pp. 249-255, 2002.
45. H. Sasaki, M. Tanahashi, H. Yukiue et al., "Decreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer," Lung Cancer, Vol. 36, no. 1, pp. 71-76, 2002.
46. C. M. Lyon, D. M. Klinge, K. C. Do et al., "Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model," Carcinogenesis, Vol. 30, no. 12, pp. 2095-2099, 2009.
47. W. G. Jiang, A. Douglas-Jones, and R. E. Mansel, "Expression of peroxisome-proliferator activated receptor-gamma (PPARγ) and the PPARγ co-activator, PGC-1, in human breast cancer correlates with clinical outcomes," International Journal of Cancer, Vol. 106, no. 5, pp. 752-757, 2003.
48. G. Magenta, X. Borenstein, R. Rolando, and M. A. Jasnis, "Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3," BMC Cancer, Vol. 8, article 47, 2008.
49. B. Bojková, M. Garajová, K. Kajo et al., "Pioglitazone in chemically induced mammary carcinogenesis in rats," European Journal of Cancer Prevention, Vol. 19, no. 5, pp. 379-384, 2010.
50. H. J. Burstein, G. D. Demetri, E. Mueller, P. Sarraf, B. M. Spiegelman, and E. P. Winer, "Use of the peroxisome proliferatoractivated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: a phase II study," Breast Cancer Research and Treatment, Vol. 79, no. 3, pp. 391-397, 2003.
51. L. D. Yee, N. Williams, P. Wen et al., "Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers," Clinical Cancer Research, Vol. 13, no. 1, pp. 246-252, 2007.
52. Y. Nakamura, T. Suzuki, A. Sugawara, Y. Arai, and H. Sasano, "Peroxisome proliferator-activated receptor gamma in human prostate carcinoma," Pathology International, Vol. 59, no. 5, pp. 288-293, 2009.
53. J.-S. Annicotte, I. Iankova, S. Miard et al., "Peroxisome proliferator-activated receptor γ regulates E-cadherin expression and inhibits growth and invasion of prostate cancer," Molecular and Cellular Biology, Vol. 26, no. 20, pp. 7561-7574, 2006.
54. E. Mueller, M. Smith, P. Sarraf et al., "Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer," Proceedings of the National Academy of Sciences of the United States of America, Vol. 97, no. 20, pp. 10990-10995, 2000.
55. J. I. Hisatake, T. Ikezoe, M. Carey, S. Holden, S. Tomoyasu, and H. P. Koeffler, "Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor γ in human prostate cancer," Cancer Research, Vol. 60, no. 19, pp. 5494-5498, 2000.
56. M. Kato, T. Nagaya, M. Fujieda, K. Saito, J. Yoshida, and H. Seo, "Expression of PPARγ and its ligand-dependent growth inhibition in human brain tumor cell lines," Japanese Journal of Cancer Research, Vol. 93, no. 6, pp. 660-666, 2002.
57. C. Grommes, D. S. Conway, A. Alshekhlee, and J. S. Barnholtz-Sloan, "Inverse association of PPARγ agonists use and high grade glioma development," Journal of Neuro-Oncology, Vol. 100, no. 2, pp. 233-239, 2010.
58. C. Grommes, J. C. Karlo, A. Caprariello, D. Blankenship, A. Dechant, and G. E. Landreth, "The PPARγ agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model," Cancer Chemotherapy and Pharmacology, Vol. 71, no. 4, pp. 929-936, 2013.
59. P. Hau, L. Kunz-Schughart, U. Bogdahn et al., "Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study," Oncology, Vol. 73, no. 1-2, pp. 21-25, 2007.
60. S. Meyer, T. Vogt, M. Landthaler et al., "Research article: Cyclooxygenase 2 (COX2) and peroxisome proliferator-activated receptor gamma (PPARG) are stage-dependent prognostic markers of malignant melanoma," PPAR Research, Vol. 2010, Article ID 848645, 10 pages, 2010.
61. A. Ferrara, J. D. Lewis, C. P. Quesenberry Jr. et al., "Cohort study of pioglitazone and cancer incidence in patients with diabetes," Diabetes Care, Vol. 34, no. 4, pp. 923-929, 2011.
62. T. Botton, A. Puissant, P. Bahadoran et al., "In vitro and in vivo anti-melanoma effects of ciglitazone," Journal of Investigative Dermatology, Vol. 129, no. 5, pp. 1208-1218, 2009.
63. R. Govindarajan, L. Ratnasinghe, D. L. Simmons et al., "Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes," Journal of Clinical Oncology, Vol. 25, no. 12, pp. 1476-1481, 2007.
64. M. Monami, I. Dicembrini, and E. Mannucci, "Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials," Acta Diabetologica, Vol. 51, no. 1, pp. 91-101, 2014.
65. S. Kawa, T. Nikaido, H. Unno, N. Usuda, K. Nakayama, and K. Kiyosawa, "Growth inhibition and differentiation of pancreatic cancer cell lines by PPARγ ligand troglitazone," Pancreas, Vol. 24, no. 1, pp. 1-7, 2002.
66. M. Kato, T. Kusumi, S. Tsuchida, M. Tanaka, M. Sasaki, and H. Kudo, "Induction of differentiation and peroxisome proliferator-activated receptor γ expression in colon cancer cell lines by troglitazone," Journal of Cancer Research and Clinical Oncology, Vol. 130, no. 2, pp. 73-79, 2004.
67. I. Jagan, A. Fatehullah, R. K. Deevi, V. Bingham, and F. C. Campbell, "Rescue of glandular dysmorphogenesis in PTEN-deficient colorectal cancer epithelium by PPARγ-targeted therapy," Oncogene, Vol. 32, no. 10, pp. 1305-1315, 2013.
68. Y. Li, Y. Meng, H. Li et al., "Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line A375," Medical Oncology, Vol. 23, no. 3, pp. 393-402, 2006.
69. A. Aiello, G. Pandini, F. Frasca et al., "Peroxisomal proliferator-activated receptor-γ agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells," Endocrinology, Vol. 147, no. 9, pp. 4463-4475, 2006.
70. E. Pestereva, S. Kanakasabai, and J. J. Bright, "PPARγ agonists regulate the expression of stemness and differentiation genes in brain tumour stem cells," British Journal of Cancer, Vol. 106, no. 10, pp. 1702-1712, 2012.
71. C. L. Varley, J. Stahlschmidt, B. Smith, M. Stower, and J. Southgate, "Activation of peroxisome proliferator-activated receptorgamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells," The American Journal of Pathology, Vol. 164, no. 5, pp. 1789-1798, 2004.
72. M.-Y. Li, A. W. Y. Kong, H. Yuan et al., "Pioglitazone prevents smoking carcinogen-induced lung tumor development in mice," Current Cancer Drug Targets, Vol. 12, no. 6, pp. 597-606, 2012.
73. I. Borbath, I. Leclercq, P. Moulin, C. Sempoux, and Y. Horsmans, "The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver," European Journal of Cancer, Vol. 43, no. 11, pp. 1755-1763, 2007.
74. J. Yu, L. Qiao, L. Zimmermann et al., "Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo," Hepatology, Vol. 43, no. 1, pp. 134-143, 2006.
75. W. Wu, J. Celestino, M. R. Milam et al., "Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model," International Journal of Gynecological Cancer, Vol. 18, no. 2, pp. 329-338, 2008.
76. S. Theocharis, J. Klijanienko, C. Giaginis et al., "Peroxisome proliferator-activated receptor-γ in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival," Journal of Cancer Research and Clinical Oncology, Vol. 137, no. 2, pp. 251-259, 2011.
77. R. Suzuki, H. Kohno, M. Suzui et al., "An animal model for the rapid induction of tongue neoplasms in human c-Ha-ras proto-oncogene transgenic rats by 4-nitroquinoline 1-oxide: its potential use for preclinical chemoprevention studies," Carcinogenesis, Vol. 27, no. 3, pp. 619-630, 2006.
78. K. Yoshida, Y. Hirose, T. Tanaka et al., "Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor γ ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide," Cancer Science, Vol. 94, no. 4, pp. 365-371, 2003.
79. H. Li, A. L. Sorenson, J. Poczobutt et al., "Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis," PLoS ONE, Vol. 6, no. 12, Article ID e28133, 2011.
80. D. Bonofiglio, E. Cione, H. Qi et al., "Combined low doses of PPARγ and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells," The American Journal of Pathology, Vol. 175, no. 3, pp. 1270-1280, 2009.
81. P. Tontonoz, S. Singer, B. M. Forman et al., "Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor," Proceedings of the National Academy of Sciences of the United States of America, Vol. 94, no. 1, pp. 237-241, 1997.
82. L. Q. Cao, X. L. Wang, Q. Wang et al., "Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARγ signaling pathway," Acta Pharmacologica Sinica, Vol. 30, no. 9, pp. 1316-1322, 2009.
83. S. Y. Lee, G. Y. Hur, K. H. Jung et al., "PPAR-γ agonist increase gefitinib's antitumor activity through PTEN expression," Lung Cancer, Vol. 51, no. 3, pp. 297-301, 2006.
84. Z. Yang, R. Bagheri-Yarmand, S. Balasenthil et al., "HER2 regulation of peroxisome proliferator-activated receptor γ (PPARγ) expression and sensitivity of breast cancer cells to PPARγ ligand therapy," Clinical Cancer Research, Vol. 9, no. 8, pp. 3198-3203, 2003.
85. G. D. Girnun, E. Naseri, S. B. Vafai et al., "Synergy between PPARγ ligands and platinum-based drugs in cancer," Cancer Cell, Vol. 11, no. 5, pp. 395-406, 2007.
86. K. Tikoo, P. Kumar, and J. Gupta, "Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benzaanthracene (DMBA) induced breast cancer rats," BMC Cancer, Vol. 9, article 107, 2009.
87. N. Hamaguchi, H. Hamada, S. Miyoshi et al., "In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth," Cancer Science, Vol. 101, no. 9, pp. 1955-1964, 2010.
88. J. A. Copland, L. A. Marlow, S. Kurakata et al., "Novel highaffinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1," Oncogene, Vol. 25, no. 16, pp. 2304-2317, 2006.
89. Y. Yokoyama, B. Xin, T. Shigeto, and H. Mizunuma, "Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers," Journal of Cancer Research and Clinical Oncology, Vol. 137, no. 8, pp. 1219-1228, 2011.
90. H. Fu, J. Zhang, J. Pan et al., "Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice," Molecular Carcinogenesis, Vol. 50, no. 12, pp. 913-921, 2011.
91. A. Reichle, K. Bross, T. Vogt et al., "Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma," Cancer, Vol. 101, no. 10, pp. 2247-2256, 2004.
92. T. Vogt, C. Hafner, K. Bross et al., "Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors," Cancer, Vol. 98, no. 10, pp. 2251-2256, 2003.
93. F. Ondrey, "Peroxisome proliferator-activated receptor γ pathway targeting in carcinogenesis: implications For Chemoprevention," Clinical Cancer Research, Vol. 15, no. 1, pp. 2-8, 2009.
94. O. Omur and Y. Baran, "An update on molecular biology of thyroid cancers," Critical Reviews in Oncology/Hematology, Vol. 90, no. 3, pp. 233-252, 2014.
95. N. Li, X. L. Du, L. R. Reitzel, L. Xu, and E. M. Sturgis, "Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980-2008," Thyroid, Vol. 23, no. 1, pp. 103-110, 2013.
96. C. F. A. Eustatia-Rutten, E. P. M. Corssmit, N. R. Biermasz, A. M. Pereira, J. A. Romijn, and J. W. Smit, "Survival and death causes in differentiated thyroid carcinoma," Journal of Clinical Endocrinology and Metabolism, Vol. 91, no. 1, pp. 313-319, 2006.
97. C. Durante, N. Haddy, E. Baudin et al., "Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy," Journal of Clinical Endocrinology and Metabolism, Vol. 91, no. 8, pp. 2892-2899, 2006.
98. O. Dohán, A. De La Vieja, V. Paroder et al., "The sodium/iodide symporter (NIS): characterization, regulation, and medical significance," Endocrine Reviews, Vol. 24, no. 1, pp. 48-77, 2003.
99. M. J. Schlumberger, "Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status," Journal of Endocrinological Investigation, Vol. 22, no. 11, pp. 3-7, 1999.
100. T. Carling and R. Udelsman, Eds., Thyroid Tumors, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 9th edition, 2011.
101. A. Versari, M. Sollini, A. Frasoldati et al., "Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients," Thyroid, Vol. 24, no. 4, pp. 715-726, 2014.
102. M. L. Martelli, R. Iuliano, I. Le Pera et al., "Inhibitory effects of peroxisome proliferator-activated receptor γ on thyroid carcinoma cell growth," Journal of Clinical Endocrinology and Metabolism, Vol. 87, no. 10, pp. 4728-4735, 2002.
103. E. Fröhlich, P. Brossart, and R. Wahl, "Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines," European Journal of Nuclear Medicine and Molecular Imaging, Vol. 36, no. 5, pp. 780-790, 2009.
104. J.-W. Park, R. Zarnegar, H. Kanauchi et al., "Troglitazone, the peroxisome proliferator-activated receptor-γ agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines," Thyroid, Vol. 15, no. 3, pp. 222-231, 2005.
105. E. Fröhlich, F. Machicao, and R. Wahl, "Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture," Endocrine-Related Cancer, Vol. 12, no. 2, pp. 291-303, 2005.
106. M. E. Dobson, E. Diallo-Krou, V. Grachtchouk et al., "Pioglitazone induces a proadipogenic antitumor response in mice with PAX8 - PPARγ fusion protein thyroid carcinoma," Endocrinology, Vol. 152, no. 11, pp. 4455-4465, 2011.
107. Y. Kato, H. Ying, L. Zhao et al., "PPARγ insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-κB signaling pathway," Oncogene, Vol. 25, no. 19, pp. 2736-2747, 2006.
108. S. J. Rosenbaum-Krumme, A. Bockisch, and J. Nagarajah, "Pioglitazone therapy in progressive differentiated thyroid carcinoma," NuklearMedizin, Vol. 51, no. 4, pp. 111-115, 2012.
109. M. Elola, A. Yoldi, J. I. Emparanza, T. Matteucci, I. Bilbao, and M. Goena, "Redifferentiation therapy with rosiglitazone in a case of differentiated thyroid cancer with pulmonary metastases and absence of radioiodine uptake," Revista Espanola de Medicina Nuclear, Vol. 30, no. 4, pp. 241-243, 2011.
110. A. N. Elias and P. Lizotte, "Enhanced radioiodine uptake in a patient with poorly differentiated papillary thyroid cancer after treatment with rosiglitazone," Clinical Nuclear Medicine, Vol. 31, no. 9, pp. 517-519, 2006.
111. J.-C. Philips, C. Petite, J.-P. Willi, F. Buchegger, and C. A. Meier, "Effect of peroxisome proliferator-activated receptor γ agonist, rosiglitazone, on dedifferentiated thyroid cancers," Nuclear Medicine Communications, Vol. 25, no. 12, pp. 1183-1186, 2004.
112. E. Kebebew, M. Peng, E. Reiff et al., "A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodinenegative differentiated thyroid cancer," Surgery, Vol. 140, no. 6, pp. 960-967, 2006.
113. S. Tepmongkol, S. Keelawat, S. Honsawek, and P. Ruangvejvorachai, "Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma," Thyroid, Vol. 18, no. 7, pp. 697-704, 2008.
114. E. Kebebew, S. Lindsay, O. H. Clark, K. A. Woeber, R. Hawkins, and F. S. Greenspan, "Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer," Thyroid, Vol. 19, no. 9, pp. 953-956, 2009.
115. E. A. Eisenhauer, P. Therasse, J. Bogaerts et al., "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)," European Journal of Cancer, Vol. 45, no. 2, pp. 228-247, 2009.
116. J. D. Burton, D. M. Goldenberg, and R. D. Blumenthal, "Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types," PPAR Research, Vol. 2008, Article ID 494161, 7 pages, 2008.
117. S. Kakiuchi-Kiyota, J. A. Vetro, S. Suzuki et al., "Effects of the PPARγ agonist troglitazone on endothelial cells in vivo and in vitro: Differences between human and mouse," Toxicology and Applied Pharmacology, Vol. 237, no. 1, pp. 83-90, 2009.
118. S. Takano, T. Kubota, H. Nishibori et al., "Pioglitazone, a ligand for peroxisome proliferator-activated receptor-γ acts as an inhibitor of colon cancer liver metastasis," Anticancer Research, Vol. 28, no. 6, pp. 3593-3599, 2008.
119. S. J. Diede, Z. Yao, C. Chip Keyes et al., "Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer," Epigenetics, Vol. 8, no. 12, pp. 1254-1260, 2013.
120. M. De Jong and T. Maina, "Of mice and humans: are they the same? - Implications in cancer translational research," Journal of Nuclear Medicine, Vol. 51, no. 4, pp. 501-504, 2010.
121. V. Vaish, L. Tanwar, and S. N. Sanyal, "The role of NF-κB and PPARγ in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors," Tumour Biology, Vol. 31, no. 5, pp. 427-436, 2010.
122. M. V. Pino, M. F. Kelley, and Z. Jayyosi, "Promotion of colon tumors in C57BL/6J-APCmin/+ mice by thiazolidinedione PPARγ agonists and a structurally unrelated PPARγ agonist," Toxicologic Pathology, Vol. 32, no. 1, pp. 58-63, 2004.
123. H. Kohno, S. Yoshitani, S. Takashima et al., "Troglitazone, a ligand for peroxisome proliferator-activated receptor γ, inhibits chemically-induced aberrant crypt foci in rats," Japanese Journal of Cancer Research, Vol. 92, no. 4, pp. 396-403, 2001.
124. E. J. Han, C. N. Im, S. H. Park, E. Y. Moon, and S. H. Hong, "Combined treatment with peroxisome proliferator-activated receptor (PPAR) gamma ligands and gamma radiation induces apoptosis by PPARγ-independent up-regulation of reactive oxygen species-induced deoxyribonucleic acid damage signals in non-small cell lung cancer cells," International Journal of Radiation Oncology Biology Physics, Vol. 85, no. 5, pp. e239-e248, 2013.
125. S. Y. James, F. Lin, S. K. Kolluri, M. I. Dawson, and X.-K. Zhang, "Regulation of retinoic acid receptor β expression by peroxisome proliferator-activated receptor γ ligands in cancer cells," Cancer Research, Vol. 63, no. 13, pp. 3531-3538, 2003.
126. A. Papi, P. Rochhi, A. M. Ferreri, F. Guerra, and M. Orlandi, "Enhanced effects of PPARγ ligands and RXR selective retinoids in combination to inhibit migration and invasiveness in cancer cells," Oncology Reports, Vol. 21, no. 4, pp. 1083-1089, 2009.
127. A. Papi, L. Tatenhorst, D. Terwel et al., "PPARγ and RXRγ ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models," Journal of Neurochemistry, Vol. 109, no. 6, pp. 1779-1790, 2009.
128. K. Bräutigam, J. Biernath-Wüpping, D. O. Bauerschlag et al., "Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines," Journal of Cancer Research and Clinical Oncology, Vol. 137, no. 5, pp. 875-886, 2011.
129. P. Mrówka, E. Glodkowska, D. Nowis et al., "Ciglitazone, an agonist of peroxisome proliferator-activated receptor γ, exerts potentiated cytostatic/cytotoxic effects against tumor cells when combined with lovastatin," International Journal of Oncology, Vol. 32, no. 1, pp. 249-255, 2008.
130. T. H. Chang and E. Szabo, "Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-γ and inhibitors of histone deacetylase in adenocarcinoma of the lung," Clinical Cancer Research, Vol. 8, no. 4, pp. 1206-1212, 2002.
131. Y. Liu, Z.-A. Zhu, S.-N. Zhang et al., "Combinational effect of PPARγ agonist and RXR agonist on the growth of SGC7901 gastric carcinoma cells in vitro," Tumor Biology, Vol. 34, no. 4, pp. 2409-2418, 2013.
132. R. C. Reddy, A. Srirangam, K. Reddy et al., "Chemotherapeutic drugs induce PPAR-γ expression and show sequence-specific synergy with PPAR-γ ligands in inhibition of non-small cell lung cancer," Neoplasia, Vol. 10, no. 6, pp. 597-603, 2008.
133. E. Elstner, E. A. Williamson, C. Zang et al., "Novel therapeutic approach: ligands for PPARγ and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells," Breast Cancer Research and Treatment, Vol. 74, no. 2, pp. 155-165, 2002.
134. B.-H. Park, S.-B. Lee, D. B. Stolz, Y. J. Lee, and B.-C. Lee, "Synergistic interactions between heregulin and peroxisome proliferator-activated receptor-γ (PPARγ) agonist in breast cancer cells," Journal of Biological Chemistry, Vol. 286, no. 22, pp. 20087-20099, 2011.
135. C.-J. Yao, G.-M. Lai, C.-F. Chan, A.-L. Cheng, Y.-Y. Yang, and S.-E. Chuang, "Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone," International Journal of Cancer, Vol. 118, no. 3, pp. 773-779, 2006.
136. K.-H. Yan, C.-J. Yao, H.-Y. Chang, G.-M. Lai, A.-L. Cheng, and S.-E. Chuang, "The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells," Molecular Carcinogenesis, Vol. 49, no. 3, pp. 235-246, 2010.
137. H.-N. Yu, E.-M. Noh, Y.-R. Lee et al., "Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells," Biochemical and Biophysical Research Communications, Vol. 377, no. 1, pp. 242-247, 2008.
138. Z. An, X. Liu, H. Song et al., "Effect of troglitazone on radiation sensitivity in cervix cancer cells," Radiation Oncology Journal, Vol. 30, no. 2, pp. 78-87, 2012.
139. Y.-Q. Zhang, X.-Q. Tang, L. Sun et al., "Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor γ," World Journal of Gastroenterology, Vol. 13, no. 10, pp. 1534-1540, 2007.
140. R. M. Cesario, J. Stone, W.-C. Yen, R. P. Bissonnette, and W. W. Lamph, "Differentiation and growth inhibition mediated via the RXR: PPARγ heterodimer in colon cancer," Cancer Letters, Vol. 240, no. 2, pp. 225-233, 2006.
141. M. Mody, N. Dharker, M. Bloomston et al., "Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-α, CH11 and CYC202," Endocrine-Related Cancer, Vol. 14, no. 2, pp. 305-315, 2007.
142. H. Koga, K. Selvendiran, R. Sivakumar et al., "PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells," International Journal of Oncology, Vol. 40, no. 3, pp. 679-685, 2012.
143. C. Freudlsperger, A. Thies, U. Pfuller, and U. Schumacher, "The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-γ agonist rosiglitazone in human melanoma cells," Anticancer Research, Vol. 27, no. 1, pp. 207-213, 2007.
144. S. Gehring, J. H. Tapia-Pérez, E. Kirches et al., "Cytotoxic effects of statins and thiazolidinediones on meningioma cells," Journal of Neuro-Oncology, Vol. 102, no. 3, pp. 383-393, 2011.
145. J. H. Tapia-Pérez, E. Kirches, C. Mawrin, R. Firsching, and T. Schneider, "Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells," Cancer Chemotherapy and Pharmacology, Vol. 67, no. 5, pp. 1193-1201, 2011.
146. E. Gottfried, S. Rogenhofer, H. Waibel et al., "Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids," Cancer Chemotherapy and Pharmacology, Vol. 67, no. 1, pp. 117-126, 2011.